Revenue: The sum of all revenue fields included for a company's operating activities.
Spero Therapeutics, Inc. (SPRO) had Revenue of $41.30M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
|
Revenue |
$41.30M |
$31.52M |
|
-- |
|
$41.30M |
|
$9.89M |
|
$31.41M |
|
$0.38M |
|
$31.78M |
|
$31.78M |
|
$31.52M |
|
$31.52M |
|
$31.52M |
|
$31.52M |
|
$31.41M |
|
$31.41M |
|
56.02M |
|
59.04M |
|
$0.56 |
|
$0.56 |
|
| Balance Sheet Financials | |
$67.29M |
|
-- |
|
$1.63M |
|
$68.92M |
|
$8.87M |
|
-- |
|
$1.03M |
|
$9.90M |
|
$59.02M |
|
$59.02M |
|
$59.02M |
|
56.41M |
|
| Cash Flow Statement Financials | |
$-12.62M |
|
-- |
|
-- |
|
$52.89M |
|
$40.27M |
|
$-12.62M |
|
$4.33M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.59 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
76.05% |
|
76.05% |
|
-- |
|
76.96% |
|
76.33% |
|
$-12.62M |
|
-- |
|
-- |
|
-- |
|
0.60 |
|
-- |
|
1.63 |
|
55.33 |
|
53.40% |
|
53.40% |
|
45.73% |
|
53.40% |
|
$1.05 |
|
$-0.21 |
|
$-0.21 |
|